Adherence and acceptance of a new oral nutritional supplement in cancer patients - a pilot study in crossover design.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Oral nutritional supplements (ONS) play a key role in the therapy of cancer-cachexia, but adherence to ONS-intake remains challenging.

The researchers compared the acceptance and adherence of a commercial liquid ONS (LS) with a newly developed, energy- and protein-rich, semisolid, fruit-gum based product (FG) in oncological patients.

Who Took Part

The abstract describes 16 participants taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, crossover and pilot study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the participants took both Copper (Supplement) and the comparison in turn, acting as their own control.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

Sensory properties were evaluated and safety monitoring was performed.

What Was Measured

Adherence to ONS was recorded with MARS-D questionnaire.

The subject headings attached to it are Neoplasms, Pilot Projects, Dietary Supplements, Quality of Life and Patient Compliance.

What This Means in Plain Language

The paper is a randomized, crossover and pilot study of Copper (Supplement) in 16 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Journal of physiology and pharmacology : an official journal of the Polish Physiological Society), a journal based in Poland.

More context: the Copper (Supplement) compound page, all human trials.